About Quantitative Medicine
Quantitative Medicine is a Healthcare company based in Pittsburgh (United States) founded in 2012, and was acquired by Predictive Oncology in January 2020. Quantitative Medicine is a biomedical analytics and computational biology company. The company was acqui-hired. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Insitro, Avidity Biosciences and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Quantitative Medicine was founded in 2012 in Pittsburgh, United States, within the biomedical analytics and computational biology sector. A drug discovery platform is operated, by which drug candidates are screened against pathogenic, cellular, molecular, and systems biology targets. Similarities in target relationships are identified using active machine learning and predictive modeling. Efficiency in drug discovery processes is thereby enhanced, with operations centered in the United States.
- Headquarters Pittsburgh, United States
- Stage Acquired
- SectorsHealthcare
- Website qtmed.com
- Social LinkedIn X
- Acquired by Predictive Oncology (Jan 2020)
- Investors
- Acquired byPredictive Oncology
(Jan 2020)
Investors in Quantitative Medicine
Quantitative Medicine has secured backing from 1 investor. Prominent investors backing the company include Predictive Oncology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AI-based platform for cancer diagnostics and precision medicine is utilized. | 2002 | predictive-oncology.com | Eagan, United States |
Investor details for Quantitative Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Quantitative Medicine
2 dated milestones of Quantitative Medicine across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Quantitative Medicine is founded.
- Exit Acquired by Predictive Oncology.
Competitors of Quantitative Medicine
Quantitative Medicine has 3 listed competitors in our database, 3 of them funded. They include Insitro, Avidity Biosciences and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Quantitative Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Quantitative Medicine
Websites that share an audience with Quantitative Medicine (qtmed.com).
Websites whose visitors overlap most with Quantitative Medicine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Quantitative Medicine (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Quantitative Medicine
Complete news archive for Quantitative Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quantitative Medicine
Quantitative Medicine was founded in 2012.
Quantitative Medicine is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Quantitative Medicine was founded in 2012 in Pittsburgh, United States, within the biomedical analytics and computational biology sector. A drug discovery platform is operated, by which drug candidates are screened against pathogenic, cellular, molecular, and systems biology targets. Similarities in target relationships are identified using active machine learning and predictive modeling. Efficiency in drug discovery processes is thereby enhanced, with operations centered in the United States.
Quantitative Medicine's top competitors include Insitro, Avidity Biosciences and Vividion Therapeutics.
Quantitative Medicine has 1 investor. Key investors include Predictive Oncology.
Yes. Quantitative Medicine was acquired by Predictive Oncology in January 2020.